⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1794347 | 0.94 | — | — | |
| SCHEMBL1242860 | 0.92 | L3MBTL1 (0.38) | — | |
| Hydrochloric Acid SCHEMBL3873748 | 0.90 | L3MBTL1 (0.37) | — | |
| SCHEMBL5149419 | 0.88 | — | — | |
| Pyrrolidine SCHEMBL2830893 | 0.82 | CA2 (0.38) | — | |
| SCHEMBL1764108 | 0.80 | CA2 (0.36) | — | |
| SCHEMBL128860 | 0.77 | KDM4E (0.45) | — | |
| SCHEMBL10578838 | 0.77 | ALDH1A1 (0.33) | — | |
| SCHEMBL7512749 | 0.75 | GNAI3 (0.33) | — | |
| SCHEMBL8784207 | 0.75 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834482-B2 | Agents modulating beta-catenin functions and methods thereof | FOG PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220213154-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11214578-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-11198713-B2 | Agents modulating beta-catenin functions and methods thereof | FOG PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200148696-A1 | Urea/Carbamates FAAH MAGL Or Dual FAAH/MAGL Inhibitors And Uses Thereof | NORTHEASTERN UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| US-10570146-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3526206-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-08-21 | — | — | EP | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| WO-2018069863-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| US-20170247387-A1 | UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF | NORTHEASTERN UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| WO-2016014975-A2 | UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2016-01-28 | — | — | WO | disclosed |
| EP-2616071-A2 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172384-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2013-07-04 | — | — | US | disclosed |
| WO-2012037299-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |